BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande AJ, Li XN, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nat Neurosci 2020;23:842-53. [PMID: 32424282 DOI: 10.1038/s41593-020-0628-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Voskamp MJ, Li S, van Daalen KR, Crnko S, Ten Broeke T, Bovenschen N. Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. Cancers (Basel) 2021;13:5387. [PMID: 34771550 DOI: 10.3390/cancers13215387] [Reference Citation Analysis]
2 Qiu B, Kline C, Mueller S. Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. Front Oncol 2021;11:674596. [PMID: 34277419 DOI: 10.3389/fonc.2021.674596] [Reference Citation Analysis]
3 Ferreira RO, Granha I, Ferreira RS, Bueno HS, Okamoto OK, Kaid C, Zatz M. Effect of Serial Systemic and Intratumoral Injections of Oncolytic ZIKVBR in Mice Bearing Embryonal CNS Tumors. Viruses 2021;13:2103. [PMID: 34696533 DOI: 10.3390/v13102103] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Xu L, Zhang H, Wang Y, Yang A, Dong X, Gu L, Liu D, Ding N, Jiang Y. FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis. Lab Invest 2021. [PMID: 34725437 DOI: 10.1038/s41374-021-00679-2] [Reference Citation Analysis]
5 Abedalthagafi M, Mobark N, Al-Rashed M, AlHarbi M. Epigenomics and immunotherapeutic advances in pediatric brain tumors. NPJ Precis Oncol 2021;5:34. [PMID: 33931704 DOI: 10.1038/s41698-021-00173-4] [Reference Citation Analysis]
6 Chai HH, Kim TH, Kim YR, Lim D. Structure and function of the porcine TAP protein and its inhibition by the viral immune evasion protein ICP47. Int J Biol Macromol 2021;178:514-26. [PMID: 33662419 DOI: 10.1016/j.ijbiomac.2021.02.196] [Reference Citation Analysis]
7 He Z, Khatib AM, Creemers JWM. The proprotein convertase furin in cancer: more than an oncogene. Oncogene 2022. [PMID: 34997216 DOI: 10.1038/s41388-021-02175-9] [Reference Citation Analysis]
8 Pasqualini C, Kozaki T, Bruschi M, Nguyen THH, Minard-Colin V, Castel D, Grill J, Ginhoux F. Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. Neuron 2020;108:1025-44. [PMID: 33065047 DOI: 10.1016/j.neuron.2020.09.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Borgenvik A, Čančer M, Hutter S, Swartling FJ. Targeting MYCN in Molecularly Defined Malignant Brain Tumors. Front Oncol 2020;10:626751. [PMID: 33585252 DOI: 10.3389/fonc.2020.626751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shiraishi R, Kawauchi D. Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models. Cancer Sci 2021;112:2948-57. [PMID: 34050694 DOI: 10.1111/cas.14990] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Boutelle AM, Attardi LD. p53 and Tumor Suppression: It Takes a Network. Trends Cell Biol 2021;31:298-310. [PMID: 33518400 DOI: 10.1016/j.tcb.2020.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
12 Kuiper JJW, Venema WJ. HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole. Front Immunol 2020;11:599558. [PMID: 33262772 DOI: 10.3389/fimmu.2020.599558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lakoduk AM, Lee CF, Chen PH. Gain-of-"endocytic' function in mutant p53 cancer cells. Int J Biochem Cell Biol 2021;131:105905. [PMID: 33359084 DOI: 10.1016/j.biocel.2020.105905] [Reference Citation Analysis]
14 Mpakali A, Stratikos E. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers (Basel) 2021;13:E134. [PMID: 33406696 DOI: 10.3390/cancers13010134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
15 Zhou C, Shen Y, Jin Y, Shen Z, Ye D, Shen Y, Deng H. A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma. Cancer Med 2022. [PMID: 35567376 DOI: 10.1002/cam4.4819] [Reference Citation Analysis]
16 Alvarado-Ortiz E, de la Cruz-López KG, Becerril-Rico J, Sarabia-Sánchez MA, Ortiz-Sánchez E, García-Carrancá A. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front Cell Dev Biol 2020;8:607670. [PMID: 33644030 DOI: 10.3389/fcell.2020.607670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
17 Siddiqui SS, Rahman S, Rupasinghe HPV, Vazhappilly CG. Dietary Flavonoids in p53-Mediated Immune Dysfunctions Linking to Cancer Prevention. Biomedicines 2020;8:E286. [PMID: 32823757 DOI: 10.3390/biomedicines8080286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chen X, Lan H, He D, Xu R, Zhang Y, Cheng Y, Chen H, Xiao S, Cao K. Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis. Front Immunol 2021;12:645839. [PMID: 34349753 DOI: 10.3389/fimmu.2021.645839] [Reference Citation Analysis]
19 Singh D, Khan MA, Siddique HR. Role of p53-miRNAs circuitry in immune surveillance and cancer development: A potential avenue for therapeutic intervention. Semin Cell Dev Biol 2021:S1084-9521(21)00076-8. [PMID: 33875349 DOI: 10.1016/j.semcdb.2021.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]